Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

TOBRAMYCIN

Form:

6 of 6 products shown

5 general benefit · 1 Limited Use

Other products in the same Health Canada class (S01A, S01AA) — coverage varies; not interchangeable

  • Framycetin (Soframycin): general benefit
  • Gentamicin (Garamycin): general benefit
  • Bacitracin zinc + polymyxin b (Polysporin): general benefit
  • Gatifloxacin (Zymar (with preservative)): not a benefit
  • Moxifloxacin (Vigamox): not a benefit

Tobrex · DIN 00614254 · 0.3% · Oph Oint

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Tobrex · DIN 00614254 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2018-08-02 · brand TOBREX · ATC S01AA12 TOBRAMYCIN · form Ointment · route Ophthalmic · ingredients TOBRAMYCIN 0.3 %/W/W · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Tobrex: Formulary list price $2.7514/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.7514 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5707 · Verify on the e-Formulary ↗ (DIN 00614254)

Source record
DIN 00614254: Tobrex Raw flags: sec3=Y Item: 520404024; group id 584; item number 1539; lccId None; manufacturer id NOV Source form: Oph Oint; strength: 0.3% Recorded listing: General benefit Source prices (unrounded): $2.7514; ministry $2.7514 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00614254 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5707
Shortage status: resolved shortage (ended 2021-02-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00614254
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Tobramycin · DIN 02241755 · 0.3% · Oph Sol

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandoz Tobramycin · DIN 02241755 Manufacturer: Sandoz Canada Inc.; listing date 2002-04-04 Health Canada: Marketed since 2005-10-08 · brand SANDOZ TOBRAMYCIN · ATC S01AA12 TOBRAMYCIN · form Solution · route Ophthalmic · ingredients TOBRAMYCIN 0.3 % · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Tobramycin: Formulary list price $1.3620/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3620 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65418 · Verify on the e-Formulary ↗ (DIN 02241755)

Source record
DIN 02241755: Sandoz Tobramycin Raw flags: sec3=Y Item: 520404020; group id 584; item number 1540; lccId None; manufacturer id SDZ Source form: Oph Sol; strength: 0.3% Recorded listing: General benefit Source prices (unrounded): $1.3620; ministry $1.3620 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02241755 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65418
Interchangeable products
Tobrex · DIN 00513962 · $1.3620
Shortage status: resolved shortage (ended 2025-10-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02241755
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Tobrex · DIN 00513962 · 0.3% · Oph Sol

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Tobrex · DIN 00513962 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2018-09-10 · brand TOBREX · ATC S01AA12 TOBRAMYCIN · form Solution · route Ophthalmic · ingredients TOBRAMYCIN 0.3 %/W/V · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $1.3620 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4571 · Verify on the e-Formulary ↗ (DIN 00513962)

Source record
DIN 00513962: Tobrex Raw flags: sec3=Y Item: 520404020; group id 584; item number 1540; lccId None; manufacturer id NOV Source form: Oph Sol; strength: 0.3% Recorded listing: General benefit Source prices (unrounded): $1.9400; ministry $1.3620 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00513962 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4571
Interchangeable products
Sandoz Tobramycin · DIN 02241755 · $1.3620
Shortage status: resolved shortage (ended 2019-02-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00513962
Shortage record checked 2026-09-13T08:10:21.292534+00:00

TOBI Podhaler · DIN 02365154 · 28mg · Inh Pd-capsule

Limited Use — Reason for Use code 472 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 472 required
Write on scriptLU code 472 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 472
Reason for Use code 472 For the management of cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections. Tobramycin is administered in alternating periods of 28 days. After 28 days of therapy, patients should stop therapy for the next 28 days, and then resume therapy for the next 28 day on / 28 day off cycle. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
TOBI Podhaler · DIN 02365154 Manufacturer: BGP Pharma ULC; listing date 2016-06-29 Health Canada: Marketed since 2020-03-11 · brand TOBI PODHALER · ATC J01GB01 TOBRAMYCIN · form Capsule · route Inhalation · ingredients TOBRAMYCIN 28 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

TOBI Podhaler: Formulary list price $14.6911/unit (unit not stated in source; not the patient's cost)

Ministry pays: $14.6911 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85000 · Verify on the e-Formulary ↗ (DIN 02365154)

Source record
DIN 02365154: TOBI Podhaler Raw flags: sec12=Y, sec3=Y Item: 081228163; group id 50; item number 0107; lccId 00265; manufacturer id BGP Source form: Inh Pd-Cap; strength: 28mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $14.6911; ministry $14.6911 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02365154 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85000
Shortage status: resolved shortage (ended 2026-03-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02365154
Shortage record checked 2026-09-13T08:10:21.292534+00:00

TOBI · DIN 02239630 · 300mg/5mL · Inh Sol-5mL Pk

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
TOBI · DIN 02239630 Manufacturer: BGP Pharma ULC; listing date 2006-10-23 Health Canada: Marketed since 2021-10-06 · brand TOBI · ATC J01GB01 TOBRAMYCIN · form Solution · route Inhalation · ingredients TOBRAMYCIN (TOBRAMYCIN SULFATE) 300 MG/5ML · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $41.0985 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63101 · Verify on the e-Formulary ↗ (DIN 02239630)

Source record
DIN 02239630: TOBI Raw flags: sec3=Y Item: 081228094; group id 51; item number 0108; lccId None; manufacturer id BGP Source form: Inh Sol-5mL Pk; strength: 300mg/5mL Recorded listing: General benefit Source prices (unrounded): $64.5832; ministry $41.0985 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02239630 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63101 Therapeutic Notes (formulary) For the management of cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections. Tobramycin is administered in alternating periods of 28 days. After 28 days of therapy, patients should stop therapy for the next 28 days, and then resume therapy for the next 28 day on / 28 day off cycle.
Interchangeable products
Teva-Tobramycin · DIN 02389622 · $41.0985
Shortage status: active shortage (reported 2025-09-02, estimated to end 2026-09-08, last updated 2026-09-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02239630
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Tobramycin · DIN 02389622 · 300mg/5mL · Inh Sol-5mL Pk

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Tobramycin · DIN 02389622 Manufacturer: Teva Canada Limited; listing date 2016-03-30 Health Canada: Marketed since 2016-02-03 · brand TEVA-TOBRAMYCIN · ATC J01GB01 TOBRAMYCIN · form Solution · route Inhalation · ingredients TOBRAMYCIN (TOBRAMYCIN SULFATE) 60 MG/ML · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Tobramycin: Formulary list price $41.0985/unit (unit not stated in source; not the patient's cost)

Ministry pays: $41.0985 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87512 · Verify on the e-Formulary ↗ (DIN 02389622)

Source record
DIN 02389622: Teva-Tobramycin Raw flags: sec3=Y Item: 081228094; group id 51; item number 0108; lccId None; manufacturer id TEV Source form: Inh Sol-5mL Pk; strength: 300mg/5mL Recorded listing: General benefit Source prices (unrounded): $41.0985; ministry $41.0985 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02389622 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87512 Therapeutic Notes (formulary) For the management of cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections. Tobramycin is administered in alternating periods of 28 days. After 28 days of therapy, patients should stop therapy for the next 28 days, and then resume therapy for the next 28 day on / 28 day off cycle.
Interchangeable products
TOBI · DIN 02239630 · $41.0985
Shortage status: resolved shortage (ended 2026-02-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02389622
Shortage record checked 2026-09-13T08:10:21.292534+00:00

TOBRAMYCIN SULFATE

3 general benefit · 1 not a benefit

Other products in the same Health Canada class (S01A, S01AA) — coverage varies; not interchangeable

  • Framycetin (Soframycin): general benefit
  • Gentamicin (Garamycin): general benefit
  • Bacitracin zinc + polymyxin b (Polysporin): general benefit
  • Gatifloxacin (Zymar (with preservative)): not a benefit
  • Moxifloxacin (Vigamox): not a benefit

Tobramycin · DIN 02241210 · 80mg/2mL · injection solution-2mL Pk

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Tobramycin · DIN 02241210 Manufacturer: Sandoz Canada Inc.; listing date 2002-04-04 Health Canada: Marketed since 2005-08-26 · brand TOBRAMYCIN INJECTION USP · ATC J01GB01 TOBRAMYCIN · form Solution · route Intramuscular, Intravenous · ingredients TOBRAMYCIN (TOBRAMYCIN SULFATE) 40 MG/ML · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Tobramycin: Formulary list price $3.1500/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3.1500 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64816 · Verify on the e-Formulary ↗ (DIN 02241210)

Source record
DIN 02241210: Tobramycin Raw flags: sec3=Y Item: 081228035; group id 52; item number 0109; lccId None; manufacturer id SDZ Source form: Inj Sol-2mL Pk; strength: 80mg/2mL Recorded listing: General benefit Source prices (unrounded): $3.1500; ministry $3.1500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02241210 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64816
Interchangeable products
Nebcin · DIN 00325449 · not recorded Tobramycin Injection USP · DIN 02502372 · $3.1500 Tobramycin Injection USP · DIN 02533103 · $3.1500
Shortage status: resolved shortage (ended 2023-02-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02241210
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Tobramycin Injection USP · DIN 02502372 · 80mg/2mL · injection solution-2mL Pk

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Tobramycin Injection USP · DIN 02502372 Manufacturer: Sterimax Inc.; listing date 2023-04-28 Health Canada: Marketed since 2021-02-17 · brand TOBRAMYCIN INJECTION USP · ATC J01GB01 TOBRAMYCIN · form Solution · route Intravenous, Intramuscular · ingredients TOBRAMYCIN (TOBRAMYCIN SULFATE) 40 MG/ML · company Sterimax inc · schedule Prescription
Check this DIN again · Health Canada product record

Tobramycin Injection USP: Formulary list price $3.1500/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3.1500 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99195 · Verify on the e-Formulary ↗ (DIN 02502372)

Source record
DIN 02502372: Tobramycin Injection USP Raw flags: sec3=Y Item: 081228035; group id 52; item number 0109; lccId None; manufacturer id STE Source form: Inj Sol-2mL Pk; strength: 80mg/2mL Recorded listing: General benefit Source prices (unrounded): $3.1500; ministry $3.1500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02502372 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99195
Interchangeable products
Nebcin · DIN 00325449 · not recorded Tobramycin · DIN 02241210 · $3.1500 Tobramycin Injection USP · DIN 02533103 · $3.1500
Shortage status: resolved shortage (ended 2023-06-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02502372
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Tobramycin Injection USP · DIN 02533103 · 80mg/2mL · injection solution-2mL Pk

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Tobramycin Injection USP · DIN 02533103 Manufacturer: Jamp Pharma Corporation; listing date 2024-06-28 Health Canada: Marketed since 2024-05-16 · brand TOBRAMYCIN INJECTION USP · ATC J01GB01 TOBRAMYCIN · form Solution · route Intravenous, Intramuscular · ingredients TOBRAMYCIN (TOBRAMYCIN SULFATE) 40 MG/ML · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Tobramycin Injection USP: Formulary list price $3.1500/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3.1500 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102212 · Verify on the e-Formulary ↗ (DIN 02533103)

Source record
DIN 02533103: Tobramycin Injection USP Raw flags: sec3=Y Item: 081228035; group id 52; item number 0109; lccId None; manufacturer id JPC Source form: Inj Sol-2mL Pk; strength: 80mg/2mL Recorded listing: General benefit Source prices (unrounded): $3.1500; ministry $3.1500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02533103 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102212
Interchangeable products
Nebcin · DIN 00325449 · not recorded Tobramycin · DIN 02241210 · $3.1500 Tobramycin Injection USP · DIN 02502372 · $3.1500
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02533103
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Nebcin · DIN 00325449 · 80mg/2mL · injection solution-2mL Pk

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-05-12 — choose a marketed DIN from the same-category list.Discontinued 2003-05-12 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-05-12 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2003-05-12 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Nebcin · DIN 00325449 Manufacturer: Eli Lilly Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2003-05-12 · brand NEBCIN INJ 40MG/ML · ATC J01GB01 TOBRAMYCIN · form Liquid · route Intravenous, Intramuscular · ingredients TOBRAMYCIN (TOBRAMYCIN SULFATE) 40 MG/ML · company Eli lilly canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Nebcin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2140 · Verify on the e-Formulary ↗ (DIN 00325449)

Source record
DIN 00325449: Nebcin Raw flags: notABenefit=Y, sec3=Y Item: 081228035; group id 52; item number 0109; lccId None; manufacturer id LIL Source form: Inj Sol-2mL Pk; strength: 80mg/2mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00325449 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2140
Interchangeable products
Tobramycin · DIN 02241210 · $3.1500 Tobramycin Injection USP · DIN 02502372 · $3.1500 Tobramycin Injection USP · DIN 02533103 · $3.1500
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00325449
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2003-05-12 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (08:12:28 Other Antibiotics) and how they are covered

Matched class: 08:12:28 Other Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CEFIXIME, CLINDAMYCIN PALMITATE Some products covered without a code (check the product listing): CEFADROXIL, CEFPROZIL, CEFTRIAXONE DISODIUM, CEFUROXIME AXETIL, CEPHALEXIN MONOHYDRATE, CLINDAMYCIN HCL, CLINDAMYCIN PHOSPHATE 08:12:28 Other Antibiotics

CEFADROXIL

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 500mg · Cap

CEFIXIME

· 4 products · General benefit · strengths: 20mg/mL, 400mg · Oral Susp, Tab

CEFPROZIL

· 17 products · General benefit (11), Listed, not a benefit (6) · strengths: 125mg/5mL, 250mg/5mL, 250mg, 500mg · Oral Susp-100mL Pk, Oral Susp-75mL Pk, Tab

CEFTRIAXONE DISODIUM

· 16 products · Listed, not a benefit (3), General benefit (10), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 0.25g/Vial, 1g/Vial, 2g/Vial, 10g/Vial · Inj Pd-Vial Pk

CEFUROXIME AXETIL

· 9 products · General benefit (7), Listed, not a benefit (2) · strengths: 125mg/5mL, 250mg, 500mg · Susp, Tab

CEPHALEXIN MONOHYDRATE

· 29 products · Listed, not a benefit (6), General benefit (23) · strengths: 250mg, 500mg, 25mg/mL, 50mg/mL · Cap, Pd for Oral Susp, Tab

CLINDAMYCIN HCL

· 20 products · Listed, not a benefit (2), General benefit (18) · strengths: 150mg, 300mg · Cap

CLINDAMYCIN PALMITATE

· 1 products · General benefit · strengths: 15mg/mL · Pd for Oral Susp

CLINDAMYCIN PHOSPHATE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 300mg/2mL · Inj Sol-2mL Pk

DALBAVANCIN HYDROCHLORIDE

· 1 products · Limited Use, codes 677 · strengths: 500mg/Vial · Pd for Sol (Preservative-Free)

RIFAXIMIN

· 1 products · Limited Use, codes 475 · strengths: 550mg · Tab

VANCOMYCIN HCL

· 4 products · Limited Use, codes 557, 558, 559, 560 (2), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 125mg, 250mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:28 and 3 more
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:14:08 Azoles

Other drugs in the same formulary class (52:04:04 Antibiotics) and how they are covered

Matched class: 52:04:04 Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: FRAMYCETIN SULFATE, FRAMYCETIN SULFATE & GRAMICIDIN & DEXAMETHASONE, GENTAMICIN & BETAMETHASONE SODIUM PHOSPHATE, GENTAMICIN SULFATE, POLYMYXIN B SULFATE & BACITRACIN (ZINC), POLYMYXIN B SULFATE & GRAMICIDIN, TOBRAMYCIN & DEXAMETHASONE 52:04:04 Antibiotics

FRAMYCETIN SULFATE

· 2 products · General benefit · strengths: 0.5% · Oph Oint-5g Pk, Oph Sol

GENTAMICIN SULFATE

· 1 products · General benefit · strengths: 0.3% · Oph Oint-3.5g Pk

POLYMYXIN B SULFATE & BACITRACIN (ZINC)

· 1 products · General benefit · strengths: 10000U & 500U/g · Oph Oint 3.5g Pk

GATIFLOXACIN

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.3% w/v · Oph Sol

MOXIFLOXACIN HYDROCHLORIDE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.5% · Oph Sol-3mL Pk (Preservative-Free)

FRAMYCETIN SULFATE & GRAMICIDIN & DEXAMETHASONE

· 1 products · General benefit · strengths: 5mg & 50mcg & 0.5mg/mL · Oph/Ot Sol

GENTAMICIN & BETAMETHASONE SODIUM PHOSPHATE

· 1 products · General benefit · strengths: 3mg & 1mg/mL · Oph/Ot Drops

POLYMYXIN B SULFATE & GRAMICIDIN

· 1 products · General benefit · strengths: 10000U & 0.025mg/mL · Oph/Ot Sol

TOBRAMYCIN & DEXAMETHASONE

· 2 products · General benefit · strengths: 0.3% & 0.1% · Oph Oint, Oph Susp

CIPROFLOXACIN AND DEXAMETHASONE

· 3 products · Limited Use, codes 509 · strengths: 0.3% w/v & 0.1% w/v · Otic Susp-7.5mL Pk (With Preservative) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:04:04
Full class listing Related classes: 52:04:12 Other Anti-Infectives, 52:08:92 Anti-Inflammatory Agents, Miscellaneous Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TOBREX (Tobramycin Ophthalmic Solution, USP) and TOBREX (Tobramycin Ophthalmic Ointment, USP) are topical antibiotic preparations indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of TOBREX. To reduce the development of drug-resistant bacteria and maintain the effectiveness of TOBREX and other antibacterial drugs, TOBREX should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. https://pdf.hres.ca/dpd_pm/00055025.PDF PM date: February 12, 2020 Source product: TOBREX; DIN 00513962; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS Tobramycin Injection USP may be indicated for the treatment of the following infections when caused by susceptible organisms: septicemia, complicated and recurrent urinary tract infections, lower respiratory infections, serious skin and soft tissue infections including burns and peritonitis and central nervous system infections caused by organisms resistant to antibiotics usually considered efficacious in these infections. Tobramycin is usually active against most strains of the following organisms in vitro and in clinical infections: • Pseudomonas aeruginosa • Proteus sp. (indole-positive and indole-negative), including Proteus mirabilis, Morganella morganii, Providencia rettgeri, and Proteus vulgaris • Escherichia coli • Klebsiella-Enterobacter-Serratia group • Citrobacter sp. • Providencia sp. • Staphylococci, including Staphylococcus aureus (coagulase-positive and coagulase- negative) Tobramycin Injection USP may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacteria… https://pdf.hres.ca/dpd_pm/00085270.PDF PM date: July 7, 2026 Source product: TOBRAMYCIN INJECTION USP; DIN 02241210; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

TOBI · DIN 02239630 Shortage status: active shortage (reported 2025-09-02, estimated to end 2026-09-08, last updated 2026-09-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02239630

Check this DIN again

Other review policies

For Nebcin: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026